Results 251 to 260 of about 690,450 (310)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Factors influencing the availability of anesthesiologists: a scoping review. [PDF]

Hum Resour Health
Keyvanlo Z, Kokabisaghi F, Yousefi M, Sedaghat A, Ebrahimipour H.   +4 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

How to evaluate long-term care insurance policy based on policy tools and PMC index model: evidence from pilot cities in China. [PDF]

Front Public Health
Wang AQ, Wang JN, Gu YC, Yuan N, Wu YH, Duan SN, Luo J, An CJ.   +7 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Shifting from a provider-centered to a person-centered model of long-term care for older patients in Korea: a narrative review. [PDF]

Ewha Med J
Ga H.
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

From security to spending: how China's long-term care insurance pilot drives urban household consumption. [PDF]

Front Public Health
Li T, Wang L.
europepmc   +1 more source

Developing models for delivering insurance through CDFIs - opportunities and risks [PDF]

, 2009
Dayson, KT, Vik, PM, Ward, A
core  

Unlocking intergenerational support: The impact of long-term care insurance on elderly family dynamics. [PDF]

PLoS One
Qu Y, Li Y, Yin A, Li J.
europepmc   +1 more source